Antiarrhythmics Versus Implantable Defibrillators (AVID)—Rationale, design, and methods

The Antiarrhythmics Versus Implantable Defibrillators (AVID) study compares a strategy of initial treatment with an implantable cardioverter-defibrillator (ICD) to a strategy of initial treatment with an antiarrhythmic drug to prevent death in patients with a history of ventricular fibrillation or h...

Full description

Saved in:
Bibliographic Details
Published in:The American journal of cardiology 1995-03, Vol.75 (7), p.470-475
Main Authors: Hallstrom, A P, Greene, H L, Wyse, D G, Zipes, D, Epstein, A E, Domanski, M J, Schron, E B
Format: Article
Language:English
Subjects:
Amiodarone
Amiodarone - therapeutic use
Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy
Antiarrhythmics
Arrhythmia
Biological and medical sciences
Cardiovascular diseases
Chemotherapy
Cross-Over Studies
Defibrillators
Defibrillators, Implantable
Drug therapy
Electrocardiography
Emergency and intensive cardiocirculatory care. Cardiogenic shock. Coronary intensive care
Fibrillation
Humans
Implantation
Intensive care medicine
Medical sciences
Patients
Prospective Studies
Quality of Life
Research Design
Sotalol - therapeutic use
Survival Analysis
Tachycardia
Tachycardia, Ventricular - drug therapy
Tachycardia, Ventricular - therapy
Transplants & implants
Ventricle
Ventricular fibrillation
Ventricular Fibrillation - drug therapy
Ventricular Fibrillation - therapy
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The Antiarrhythmics Versus Implantable Defibrillators (AVID) study compares a strategy of initial treatment with an implantable cardioverter-defibrillator (ICD) to a strategy of initial treatment with an antiarrhythmic drug to prevent death in patients with a history of ventricular fibrillation or hemodynamically compromising ventricular tachycardia, or both. Neither arrhythmia can have been due to a transient or correctable cause. The principle exclusions are a contraindication to amiodarone therapy and inability to undergo ICD implantation. Antiarrhythmic drug therapy includes empiric amiodarone and guided sotalol. The ICDs allowed are advanced generation devices, and most are implanted transvenously. The primary end point of the study is total mortality. Secondary end points are cost and quality of life. The study was designed in 2 phases. The pilot phase enrolled 200 patients between June 1993 and June 1994. Data collected during the pilot phase confirmed that the trial is feasible. An additional 1,000 patients will be enrolled between June 1994 and March 1997. It is anticipated that all 1,200 patients will be followed until September 1998, and will be included in the intention-to-treat analysis.
ISSN:0002-9149
1879-1913
DOI:10.1016/S0002-9149(99)80583-9